Tocilizumab en artritis reumatoideTocilizumab in rheumatoid arthritis
Section snippets
Conflicto de intereses
Los autores declaran no tener ningún conflicto de intereses.
Bibliografía (15)
La interleucina 6 en la fisiopatología de la artrirtis reumatoide
Reumatol Clin.
(2009)- et al.
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
Arthritis Rheum.
(2006) - et al.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Mod Rheumatol.
(2009) - et al.
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab
Ann Rheum Dis.
(2007) - et al.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial
Lancet.
(2008) - et al.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study
Arthritis Rheum.
(2008) - et al.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therpy study
Arthritis Rheum.
(2008)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2010 Elsevier España, S.L. All rights reserved.